Kellogg(US:K) ZACKS·2025-05-01 15:00Core Insights - Kellanova reported $3.08 billion in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.7% and an EPS of $0.90, down from $1.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $3.11 billion by 0.78%, and the EPS was 8.16% below the consensus estimate of $0.98 [1] Financial Performance Metrics - Net sales in the AMEA region decreased by 13.6%, compared to an estimated decline of 11.2% [4] - In Latin America, net sales saw a volume impact decline of 6.2%, against an expected increase of 0.3% [4] - Total reported growth in AMEA was 3.3%, surpassing the estimated decline of 4.7% [4] - Total reported growth in Latin America was -15.2%, worse than the estimated decline of 8.9% [4] - Total reported growth in Europe was -3.4%, compared to an estimated decline of 2.1% [4] - Total reported growth in North America was -4.1%, against an estimated decline of 1.5% [4] - Net sales in North America were $1.62 billion, below the estimated $1.66 billion, representing a year-over-year decline of 4.1% [4] - Net sales in AMEA were $620 million, exceeding the estimated $571.91 million, showing a year-over-year increase of 3.3% [4] - Net sales in Latin America were $266 million, below the estimated $285.85 million, reflecting a year-over-year decline of 15.3% [4] - Net sales in Europe were $579 million, slightly below the estimated $586.27 million, indicating a year-over-year decline of 3.3% [4] Stock Performance - Kellanova shares returned +0.4% over the past month, while the Zacks S&P 500 composite declined by -0.7% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]